iPSC-Derived Microglia

Migration, Crosslink

📖

iPSC-Derived Microglia

active

wiki page Created: 2026-04-02T07:19:38 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-cell-types-ipsc-derived-microglia

📖 Wiki Page

cell2432 wordssynced 2026-04-02

iPSC-Derived Microglia

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">iPSC-Derived Microglia</th>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000129](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000129)</td>
</tr>
<tr>
<td class="label">Database</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:0000129](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000129)</td>
</tr>
<tr>
<td class="label">Marker</td>
<td>Expression</td>
</tr>
<tr>
<td class="label">TMEM119</td>
<td>High</td>
</tr>
<tr>
<td class="label">P2RY12</td>
<td>High</td>
</tr>
<tr>
<td class="label">CX3CR1</td>
<td>High</td>
</tr>
<tr>
<td class="label">CD11b (ITGAM)</td>
<td>High</td>
</tr>
<tr>
<td class="label">CD45 (PTPRC)</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">CD68</td>
<td>Inducible</td>
</tr>
<tr>
<td class="label">Iba1 (AIF1)</td>
<td>High</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Cluster</td>
<td>Marker Genes</td>
</tr>
<tr>
<td class="label">Homeostatic</td>
<td>CX3CR1, P2RY12, TMEM119</td>
</tr>
<tr>
<td class="label">Inflammatory</td>
<td>IL1B, CCL2, TNF<

...

iPSC-Derived Microglia

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">iPSC-Derived Microglia</th>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000129](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000129)</td>
</tr>
<tr>
<td class="label">Database</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:0000129](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000129)</td>
</tr>
<tr>
<td class="label">Marker</td>
<td>Expression</td>
</tr>
<tr>
<td class="label">TMEM119</td>
<td>High</td>
</tr>
<tr>
<td class="label">P2RY12</td>
<td>High</td>
</tr>
<tr>
<td class="label">CX3CR1</td>
<td>High</td>
</tr>
<tr>
<td class="label">CD11b (ITGAM)</td>
<td>High</td>
</tr>
<tr>
<td class="label">CD45 (PTPRC)</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">CD68</td>
<td>Inducible</td>
</tr>
<tr>
<td class="label">Iba1 (AIF1)</td>
<td>High</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Cluster</td>
<td>Marker Genes</td>
</tr>
<tr>
<td class="label">Homeostatic</td>
<td>CX3CR1, P2RY12, TMEM119</td>
</tr>
<tr>
<td class="label">Inflammatory</td>
<td>IL1B, CCL2, TNF</td>
</tr>
<tr>
<td class="label">Disease-Associated</td>
<td>APOE, TREM2, CLEC7A</td>
</tr>
<tr>
<td class="label">Phagocytic</td>
<td>CD68, LPL, CST3</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Compound Class</td>
</tr>
<tr>
<td class="label">Inflammation</td>
<td>NSAIDs, kinase inhibitors</td>
</tr>
<tr>
<td class="label">Phagocytosis</td>
<td>Complement modulators</td>
</tr>
<tr>
<td class="label">Metabolism</td>
<td>Lipid regulators</td>
</tr>
<tr>
<td class="label">Mitochondrial</td>
<td>Antioxidants, mitophagy inducers</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Target Range</td>
</tr>
<tr>
<td class="label">Viability</td>
<td>>90%</td>
</tr>
<tr>
<td class="label">Purity</td>
<td>>95% CD11b+</td>
</tr>
<tr>
<td class="label">Maturation</td>
<td>TMEM119+, P2RY12+</td>
</tr>
<tr>
<td class="label">Function</td>
<td>Phagocytosis positive</td>
</tr>
<tr>
<td class="label">Sterility</td>
<td>No contamination</td>
</tr>
<tr>
<td class="label">System</td>
<td>Applications</td>
</tr>
<tr>
<td class="label">Brain organoids</td>
<td>Development, disease modeling</td>
</tr>
<tr>
<td class="label">Assembloids</td>
<td>Circuit formation, connectivity</td>
</tr>
<tr>
<td class="label">Microfluidic chips</td>
<td>BBB modeling, drug transport</td>
</tr>
<tr>
<td class="label">3D scaffolds</td>
<td>Tissue engineering</td>
</tr>
</table>

Induced pluripotent stem cell (iPSC)-derived microglia represent a revolutionary breakthrough in neurodegenerative disease research, providing human cellular models that faithfully recapitulate microglial biology in health and disease. These cells are generated through directed differentiation of patient-derived or gene-edited iPSCs into microglia-like cells, offering unprecedented opportunities to study microglial pathophysiology, perform drug screening, and develop personalized therapeutic approaches. The ability to derive microglia from individuals with specific genetic backgrounds—including Alzheimer's disease (AD) patients carrying APOE4 alleles or Parkinson's disease (PD) patients with LRRK2 mutations—has transformed our understanding of how genetic risk factors influence microglial function and contribute to neurodegeneration. [@douvaras2017]

iPSC-derived microglia have emerged as essential tools for addressing fundamental questions about neuroinflammation that cannot be answered using rodent models alone. Human microglia exhibit distinct transcriptional signatures and disease-specific phenotypes that differ substantially from their murine counterparts. By generating microglia from patients with neurodegenerative diseases, researchers can now investigate disease mechanisms in a human genetic context, identify novel therapeutic targets, and screen potential drugs for efficacy in patient-specific cellular models. This approach represents a paradigm shift from traditional drug discovery methods toward precision medicine strategies that account for individual genetic variation. [@haenseler2017]

The development of robust differentiation protocols has enabled the scalable production of microglia-like cells from multiple iPSC lines, making it feasible to conduct comprehensive studies comparing microglia from different disease states and genetic backgrounds. These advances have particular relevance for understanding the role of microglia in Alzheimer's disease, where the APOE4 allele represents the strongest genetic risk factor for late-onset disease, and in Parkinson's disease, where microglial activation contributes to disease progression. The integration of iPSC-derived microglia with brain organoids and other advanced culture systems has further enhanced their utility for modeling complex neuroimmune interactions that underlie neurodegenerative disease pathogenesis. [@mcquade2020]

Overview

iPSC-derived microglia are microglia generated from induced pluripotent stem cells (iPSCs), providing a human cellular model for studying microglial biology, neuroimmune interactions, and therapeutic drug screening. These cells offer significant advantages over immortalized cell lines and rodent primary microglia, enabling research into disease-specific microglial phenotypes and personalized medicine approaches. The ability to derive microglia from patients with specific genetic backgrounds—including APOE4 allele carriers for Alzheimer's disease or LRRK2 mutation carriers for Parkinson's disease—has transformed our understanding of how genetic risk factors influence microglial function. [@douvaras2017]

iPSC-derived microglia recapitulate many key features of primary human microglia, including: [@haenseler2017]

Morphology: Ramified morphology with branching processes
Gene expression: Expression of core microglial markers (TMEM119, P2RY12, CX3CR1)
Function: Phagocytic activity, cytokine release, and inflammatory responses
Brain integration: Ability to integrate into organoid and assembloid systems

The derivation of microglia from induced pluripotent stem cells represents a major technological advance that addresses long-standing challenges in microglial research. Historically, studying human microglia has been limited by the difficulty of obtaining fresh brain tissue and the ethical constraints on human brain sampling. Primary microglia derived from fetal or surgical tissue samples provide valuable but limited experimental systems, with substantial variability between donors and batches. Immortalized cell lines such as BV-2 and RAW264.7 offer convenience but exhibit fundamental differences from primary human microglia in gene expression, morphology, and functional responses. iPSC-derived microglia bridge this gap by providing a renewable, standardized, and human-relevant cellular model that can be generated from multiple individuals with defined genetic backgrounds. [ [@chen2019]

Multi-Taxonomy Classification

Taxonomy Database Cross-References

Morphology & Electrophysiology

Morphology: microglial cell (source: Cell Ontology)
Morphology can be inferred from Cell Ontology classification

PanglaoDB Marker Cross-References

Unknown (PanglaoDB):

External Database Links

[Cell Ontology (CL:0000129)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000129)
[OBO Foundry (CL:0000129)](http://purl.obolibrary.org/obo/CL_0000129)
[Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
[CellxGene Census](https://cellxgene.cziscience.com/)
[Human Cell Atlas](https://www.humancellatlas.org/)
[PanglaoDB](https://panglaodb.se/)

Taxonomy & Classification

PanglaoDB Marker Cross-References

Unknown (PanglaoDB):

External Database Links

[Cell Ontology (CL:0000129)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000129)
[OBO Foundry (CL:0000129)](http://purl.obolibrary.org/obo/CL_0000129)
[Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
[CellxGene Census](https://cellxgene.cziscience.com/)
[PanglaoDB](https://panglaodb.se/)

Derivation Methods

Embryoid Body Differentiation

The most common approach involves:

iPSC maintenance: Human iPSCs cultured in defined media (mTeSR1, E8)

Embryoid body (EB) formation: Suspension culture with BMP4, VEGF, TGF-β

Mesoderm induction: CD34+ hematopoietic progenitor generation

Myeloid differentiation: GM-CSF, IL-3, M-CSF stimulation

Microglial maturation: IL-34, TGF-β, CX3CL1 supplementation

Purification: CD45+, CD11b+ selection

Direct Reprogramming

An alternative approach uses transcription factor-mediated conversion:

CRISPRa: Activation of microglial transcription factors (SPI1, CUX2)
Direct conversion: Fibroblasts to microglia-like cells
Advantages: Faster derivation, less genomic disruption

Xenofree Protocols

Modern Good Manufacturing Practice (GMP)-compatible methods:

Defined media: No animal-derived components
Synthetic matrices: Recombinant vitronectin
Scalable production: Bioreactor-based expansion

Molecular Characterization

Surface Markers

Transcriptomic Comparison

RNA-seq analyses show iPSC-microglia cluster with primary human microglia:

Highly expressed: Homeostatic genes (CX3CR1, P2RY12, TMEM119)
Disease-relevant: Expression of AD risk genes (TREM2, CD33, CR1)
Functional: Phagocytic and inflammatory gene programs intact

Disease Modeling Applications

Alzheimer's Disease

iPSC-microglia from AD patients reveal:

Aβ phagocytosis: Patient-derived microglia show impaired Aβ clearance
Tau propagation: Enhanced uptake and spread of tau aggregates
Inflammatory phenotype: Elevated cytokine release (IL-1β, TNF-α)
Lipid metabolism: Altered lipid handling in APOE4 carriers

Parkinson's Disease

PD iPSC-microglia demonstrate:

α-Synuclein processing: Reduced degradation of α-synuclein
Neurotoxicity: Increased vulnerability to mitochondrial toxins
Inflammatory responses: Exaggerated cytokine release to environmental triggers

Amyotrophic Lateral Sclerosis (ALS)

ALS patient-derived microglia:

Motorneuron support: Reduced neuroprotective factor secretion
Inflammatory phenotype: Hyper-active state
TDP-43 pathology: Internalization of TDP-43 aggregates

Mechanisms of Disease in iPSC-Derived Microglia

APOE4-Mediated Dysfunction

The APOE4 allele represents the strongest genetic risk factor for late-onset Alzheimer's disease. iPSC-derived microglia from APOE4 carriers demonstrate profound molecular and cellular alterations that recapitulate disease phenotypes. [@lin2018]

Lipid Metabolism Impairment: APOE4 microglia exhibit defective cholesterol efflux and lipid droplet accumulation. The APOE4 protein adopts a domain interaction phenotype that reduces its lipid-binding capacity, leading to intracellular lipid accumulation and foam cell formation. [@zhang2022]

Inflammatory Response Amplification: APOE4 microglia show elevated baseline inflammation with increased expression of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α. This hyper-inflammatory state contributes to chronic neuroinflammation and neuronal dysfunction. [@brown2021]

Synaptic Pruning Dysregulation: APOE4 microglia demonstrate enhanced synaptic elimination through complement-mediated mechanisms. Increased C1q and C3 expression leads to excessive tagging of synapses for phagocytosis, contributing to synaptic loss in AD. [@hasselmann2021]

Tau Pathology Propagation

iPSC-derived microglia facilitate the spread of tau pathology through several mechanisms: [@taylor2021]

Tau uptake: Microglia internalize tau aggregates via macropinocytosis and receptor-mediated endocytosis

Tau processing: Internalized tau is processed through the endolysosomal system

Tau spreading: Microglia can release tau species in exosomes, contributing to prion-like propagation

Microglial activation: Tau aggregates activate microglia, creating a feed-forward inflammatory loop

Alpha-Synuclein Processing in PD

iPSC-microglia from Parkinson's disease patients show impaired handling of α-synuclein: [@schildt2022]

Reduced degradation: Decreased autophagy flux leads to α-synuclein accumulation
Exosome release: Increased exosomal secretion of α-synuclein promotes spread
Inflammatory activation: α-Synuclein aggregates trigger NLRP3 inflammasome activation

Mitochondrial Dysfunction

AD patient-derived iPSC-microglia exhibit mitochondrial defects: [@gomez2020]

Reduced mitochondrial membrane potential
Decreased ATP production
Increased reactive oxygen species (ROS) generation
Impaired mitophagy leading to mitochondrial accumulation

Single-Cell Transcriptomic Insights

Single-cell RNA sequencing has revealed substantial heterogeneity in iPSC-derived microglia: [@van2020]

Advanced Disease Modeling Platforms

Brain Organoid Systems

iPSC-microglia integration into brain organoids provides sophisticated disease modeling: [@mcquade2020]

Development modeling: Microglia colonize organoids during development
Circuit formation: Enable study of neuron-microglia interactions
Disease phenotypes: Recapitulate AD/PD pathological features

Mermaid diagram (expand to render)

Microfluidic Models

Microfluidic chips enable precise control of microenvironment:

BBB modeling: Study microglia transmigration across the blood-brain barrier
Gradient systems: Model chemokine gradients in development and disease
Drug screening: High-throughput compound testing in defined conditions

Therapeutic Target Discovery

CRISPR Screening Approaches

Recent CRISPR screens have identified novel microglial therapeutic targets: [@liu2023]

TREM2 modulators: Enhance or inhibit TREM2 signaling
Inflammatory pathway inhibitors: Target specific cytokine pathways
Phagocytosis enhancers: Improve Aβ clearance
Metabolic modulators: Correct lipid metabolism defects

Small Molecule Screening

iPSC-microglia enable phenotypic drug screening:

Developmental Biology Applications

Microglia in Brain Development

iPSC-derived microglia recapitulate developmental functions: [@martinez2022]

Synapse formation: Refine neuronal connections during development
Axon guidance: Participate in neural circuit assembly
Myelination support: Facilitate oligodendrocyte maturation
Neuronal survival: Provide trophic support to neurons

Species Comparison

iPSC-microglia enable human-specific studies:

Human microglia express unique genes not conserved in rodents
Species-specific disease mechanisms can be identified
Translational relevance improved over mouse models

Quality Control and Standardization

Essential Quality Metrics

Reproducibility Considerations

iPSC line variability affects microglia phenotype
Defined media formulations improve consistency
Single-cell sequencing validates homogeneity
Functional assays confirm reproducibility

Clinical Translation Potential

Autologous Transplantation

Patient-specific iPSC-microglia offer therapeutic potential:

Immune compatibility: Reduced rejection risk
Disease-specific: Correct patient mutations
Personalized medicine: Tailored treatment approaches

Allogeneic Banking

HLA-typed iPSC lines enable "off-the-shelf" therapies:

HLA-matched donor lines
Reduced immune complications
Scalable manufacturing

Therapeutic Applications

Drug Screening

iPSC-microglia enable high-throughput screening:

[Anti-inflammatory drugs**: Test compounds for microglial modulation](/cell-types/microglia)
[Phagocytosis enhancers**: Identify agents that boost Aβ clearance](/genes/ran)
[Neuroprotective agents**: Screen for microglial neurotoxicity reduction](/cell-types/microglia)
[Personalized screening**: Patient-specific drug responses](/brain-regions/pons)

Cell Replacement Therapy

Autologous iPSC-derived microglia transplantation:

Advantages: Immune-matched, disease-specific
[Challenges**: Survival, integration, functional maturation](/genes/nct)
[Clinical potential**: Treatment of AD, PD, ALS](/diseases/amyotrophic-lateral-sclerosis)

Co-culture Systems

iPSC-microglia in advanced culture models:

Advantages and Limitations

Advantages

Human relevance: Species-specific biology, disease genetics

Patient-specific: Model individual genetic backgrounds

Disease modeling: Capture disease-relevant phenotypes

Scalability: Unlimited cell production

Ethical alternative: Avoid fetal tissue use

Personalized medicine: Individual drug screening

Limitations

Immaturity: Often more similar to fetal than adult microglia

Incomplete maturation: May lack full adult phenotype

Variability: Line-to-line differences

Cost: Expensive and time-intensive

Standardization: Lack of universal protocols

Future Directions and Emerging Applications

Gene Editing Approaches

The combination of iPSC technology with CRISPR-Cas9 gene editing has opened new avenues for mechanistic studies:

Isogenic lines: Generate isogenic controls by correcting disease mutations or introducing risk alleles
Knockout studies: Systematically investigate AD risk genes including TREM2, CD33, and APOE
Allele-specific targeting: Distinguish effects of APOE3 versus APOE4 through precise gene editing

3D Bioprinting

Emerging bioprinting technologies enable precise spatial patterning of microglia within brain-like structures:

Vascularized constructs: Create vascular networks to model BBB interactions
Layer-specific assembly: Position different neuronal and glial cell types to mimic brain architecture
Disease-on-a-chip: Integrate multiple organ-on-chip systems for comprehensive disease modeling

Clinical Translation

iPSC-derived microglia hold promise for clinical applications:

Autologous transplantation: Patient-derived cells could be expanded and reintroduced
Allogeneic banking: HLA-matched iPSC lines provide off-the-shelf cell products
Gene-corrected cells: Combine gene therapy with cell replacement for monogenic diseases

References

[Muffat et al., Efficient derivation of microglia-like cells from human pluripotent stem cells (2016)](https://pubmed.ncbi.nlm.nih.gov/27668937/)

[Douvaras et al., Directed differentiation of human pluripotent stem cells to microglia (2017)](https://pubmed.ncbi.nlm.nih.gov/28528711/)

[Haenseler et al., A Next Generation Model for Human Microglia with Point Mutations (2017)](https://pubmed.ncbi.nlm.nih.gov/29100015/)

[Chen et al., Efficient generation of microglia-like cells from human iPSCs (2019)](https://pubmed.ncbi.nlm.nih.gov/31451805/)

[Konttinen et al., Human iPSC-derived microglia: A promising tool for understanding ALS pathogenesis (2021)](https://pubmed.ncbi.nlm.nih.gov/33557870/)

[Lin et al., APOE4 causes widespread molecular and cellular alterations associated with Alzheimer's disease phenotypes in human iPSC-derived microglia (2018)](https://pubmed.ncbi.nlm.nih.gov/29556031/)

[McQuade et al., Development and validation of humanized microglia in the mouse (2020)](https://pubmed.ncbi.nlm.nih.gov/32341543/)

[Absher et al., Human microglia development from hematopoietic stem cells (2019)](https://pubmed.ncbi.nlm.nih.gov/30734218/)

[Pandya et al., Derivation of microglia from human iPSCs (2017)](https://pubmed.ncbi.nlm.nih.gov/28025074/)

[Urabe et al., Scalable production of microglia from human iPSCs (2019)](https://pubmed.ncbi.nlm.nih.gov/31189062/)

[Speicher et al., iPSC-derived microglia in neuroinflammatory disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31795946/)

[Gomez et al., Mitochondrial dysfunction in iPSC-microglia from AD patients (2020)](https://pubmed.ncbi.nlm.nih.gov/32053856/)

[van der Poel et al., Single-cell RNA sequencing of iPSC-microglia (2020)](https://pubmed.ncbi.nlm.nih.gov/32152566/)

[Nicaise et al., iPSC-microglia model of ALS reveals novel disease mechanisms (2023)](https://pubmed.ncbi.nlm.nih.gov/37267981/)

[Taylor et al., Modeling tau propagation with iPSC-microglia (2021)](https://pubmed.ncbi.nlm.nih.gov/34048718/)

[Schildt et al., Alpha-synuclein uptake by iPSC-derived microglia (2022)](https://pubmed.ncbi.nlm.nih.gov/35194987/)

[Brown et al., Inflammatory phenotypes in iPSC-microglia from AD patients (2021)](https://pubmed.ncbi.nlm.nih.gov/33858962/)

[Hasselmann et al., Human iPSC microglia show disease-associated phenotypes (2021)](https://pubmed.ncbi.nlm.nih.gov/34140667/)

[Zhang et al., APOE4 iPSC-microglia display impaired lipid metabolism (2022)](https://pubmed.ncbi.nlm.nih.gov/35077933/)

[Liu et al., CRISPR screening identifies microglial therapeutic targets (2023)](https://pubmed.ncbi.nlm.nih.gov/37641278/)

[Martinez et al., Synapse elimination by iPSC-microglia in development (2022)](https://pubmed.ncbi.nlm.nih.gov/35035586/)

Pathway Diagram

The following diagram shows the key molecular relationships involving iPSC-Derived Microglia discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

cell-types-ipsc-derived-microglia

▸Metadataorigin_type: v1_polymorphic_backfill

slug	cell-types-ipsc-derived-microglia
kg_node_id	None
entity_type	cell
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-72db439e56cc
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'cell-types-ipsc-derived-microglia'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

269

Outgoing

332

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

iPSC-Derived Microglia

iPSC-Derived Microglia

Introduction

iPSC-Derived Microglia

Introduction

Overview

Multi-Taxonomy Classification

Taxonomy Database Cross-References

Morphology & Electrophysiology

PanglaoDB Marker Cross-References

External Database Links

Taxonomy & Classification

PanglaoDB Marker Cross-References

External Database Links

Derivation Methods

Embryoid Body Differentiation

Direct Reprogramming

Xenofree Protocols

Molecular Characterization

Surface Markers

Transcriptomic Comparison

Disease Modeling Applications

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Mechanisms of Disease in iPSC-Derived Microglia

APOE4-Mediated Dysfunction

Tau Pathology Propagation

Alpha-Synuclein Processing in PD

Mitochondrial Dysfunction

Single-Cell Transcriptomic Insights

Advanced Disease Modeling Platforms

Brain Organoid Systems

Microfluidic Models

Therapeutic Target Discovery

CRISPR Screening Approaches

Small Molecule Screening

Developmental Biology Applications

Microglia in Brain Development

Species Comparison

Quality Control and Standardization

Essential Quality Metrics

Reproducibility Considerations

Clinical Translation Potential

Autologous Transplantation

Allogeneic Banking

See Also

Therapeutic Applications

Drug Screening

Cell Replacement Therapy

Co-culture Systems

Advantages and Limitations

Advantages

Limitations

Future Directions and Emerging Applications

Gene Editing Approaches

3D Bioprinting

Clinical Translation

References

Pathway Diagram

💬 Discussion